Showing 18 of 18 recruiting trials for “Mantle cell lymphoma”
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingNCT06788652 ↗
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
👨⚕️ Preetesh Jain, MBBS, MD, DM, PhD, M.D. Anderson Cancer Center📍 1 site📅 Started May 2024View details ↗
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
👨⚕️ Yucai Wang, Academic and Community Cancer Research United📍 2 sites📅 Started Jan 2024View details ↗
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
👨⚕️ Marco Ladetto, S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo" di Alessandria📍 21 sites📅 Started Mar 2022View details ↗
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
👨⚕️ Stephen D Smith, Academic and Community Cancer Research United📍 7 sites📅 Started Aug 2021View details ↗
Avo In R/R And Previously Untreated MCL
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
👨⚕️ Martin Dreyling, Prof., Klinikum der Universität München📍 112 sites📅 Started Jul 2016View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →